SNY

Sanofi-Aventis S.A.

Biotechnology

Read This Before You Play a Single One of the Biotechs Fighting COVID-19

by

Georgia, South Carolina, and Florida have announced that they are loosening quarantine restrictions; at least 13 more states have announced plans or "roadmaps" to do more or less the same thing.

There's an urgent desire to get "back to normal" as quickly as possible because the social and economic devastation – record unemployment, more than 55,300 deaths, massive lockdowns, shrinking GDP, and of course the virus itself – of the coronavirus pandemic has been so profound.

And this has all happened in a little more than a month. People are understandably anxious to put all this behind them, myself very much included.

But the stakes of "normalcy" are higher than we're being told. The successful reemergence of people into the world will require far more than just repeated reminders to wash your hands and not touch your face.

Social distancing and limited interaction can slow the spread; there's mounting evidence in the United States and other countries that we've done precisely that. But it's far from clear how much those actions could really prevent widespread illness as lockdowns ease and stay-at-home orders are lifted.

Because it's very likely that we won't be truly "safe" until a proven treatment and effective vaccine are available.

The more we learn about this virus, the more we're aware of why its ongoing impact, and the "right" way to reopen the economy, remain so uncertain.

Here's what we do know… Full Story

Here's what we do know... Full Story

Dow Jones

The Dow Jones Industrial Average Will Dip as New Tariff Deadline Approaches

by

The Dow Jones Industrial Average could lose a few as the deadline for a fresh set of U.S. tariffs on China inches nearer.

Investors are hoping that China and the United States will be able to enact a "phase one" deal to avoid the December 15 tariffs.

This would set the two nations on a path toward a more robust deal heading into 2020.

Read more...

Stocks

3 Best Dividend Stocks for Retirees with 3%-Plus Yields

by

Finding reliable retirement income is harder than ever thanks to the Fed's policies, which have led to rock-bottom interest rates. And with stocks trading at all-time highs, even decent dividend income is hard to come by.

For those investors who already have a retirement plan in place and still have extra money to invest, Money Morning has a strategy to supplement your main retirement income.

Here are the three best dividend stocks for retirees looking to supplement their retirement income with yields over 3%.

Stocks

3 Biotech Stocks to Buy Now for Gains Up to 93%

by

Finding the best biotech stocks to buy now can be exhausting, especially when investors have to read pages of technical jargon to find out what each company does.

That's why we've made it easy for Money Morning readers.

We've put together a list of the three best biotech stocks to buy right now, including our top biotech stock with the potential for 93% growth in a year...

stocks

3 of the Top Pharmaceutical Stocks to Buy Now

by

Our top pharmaceutical stocks to buy are all expected to have double-digit gains, making now a great time to buy.

With new drugs on the market, these companies have revenue coming in to fund pipeline developments. These pipeline developments will fuel revenue growth for years to come.

One of the stocks on our list is expected to gain as much as 172% in the next 12 months...

Stocks

Biotech News: This Trend Will Revolutionize the $1.6 Trillion Biopharmaceutical Sector

by

The latest biotech news is showing a revolutionary drug development process that will completely change the way biotech companies develop new drugs.

The technology can also net investors huge gains if they get in before Wall Street figures out how to invest in it.

Here's how you can get in on the ground level of this revolutionary new technology...

Biotechnology

Artificial Intelligence and Biotech Are Merging to Bring You Monster Profits

by

In biotech, one thing isn't going to change.

The "bread and butter" technology that makes up 90% of the pharmaceutical market – good, old-fashioned small molecules, created in the laboratory – isn't going anywhere.

Yes, incredibly innovative treatments like T-cell therapy and microbiome therapies (and firms like Bill Gates' new favorite $6 million company) are all having a huge impact on healthcare.

But we use small, synthetic molecules to create everything from aspirin and corticosteroids to sofosbuvir (Sovaldi) and ivacaftor (Kalydeco) – and we'll keep doing so for a long time to come.

The small molecule technique dates back to the 1890s, but that doesn't mean innovation cannot happen within that field. Scientists are always hard at work in the labs, creating cutting-edge drugs, often tailored to treat a very specific disease or subset of patients.

Meanwhile, I've turned up a tiny British company that's using its artificial intelligence (AI) platform discover promising small molecule treatments faster – and cheaper – than ever before.

I call it "biointelligence."

It's a perfect illustration of the "Convergence Economy" we talk so much about here. By combining two or more fields of tech – in this case biotech and AI – it's like a formula in which 1 + 1 = 3… and often a lot more that.

Today, we're going to learn all about this tiny company and its brand-new biointelligence technology.

This company is privately held – so if you ask, Wall Street will say you can't invest in it. But I've found a way you can.

In fact, I've found two ways.

Both of them will lead you to outsized returns – and hefty dividends.

Let's take a look...

stocks

3 of the Best Biotech Stocks to Buy Now

by

We've put together a list of our top three best biotech stocks to buy now.

All three of them have a potential catalyst that could spur massive gains in the next year, and one of these biotech stocks could gain over 180% in 12 months.

Another one of these biotech stocks isn't even on analysts' radar but has big potential with a recent acquisition to expand the share of the flu vaccine market they control...